Modern Inhalational Anesthetics for Refractory Status Epilepticus

Frederick A. Zeiler, Kaitlin J. Zeiler, Jeanne Teitelbaum, Lawrence M. Gillman, Michael West

ABSTRACT: Background: Our goal was to perform a systematic review of the literature on the use of modern inhalational anesthetic agents for refractory status epilepticus and their impact on seizure control. Methods: All articles from MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, Scopus, Cochrane Library, the International Clinical Trials Registry Platform (inception to March 2014), reference lists of relevant articles, and gray literature were searched. The strength of evidence was adjudicated using both the Oxford and Grading of Recommendation Assessment Development and Education methodology by two independent reviewers. Results: Overall, 19 studies were identified, with 16 manuscripts and 3 meeting abstracts. A total of 46 patients were treated. Adult (n = 28) and pediatric patients (n = 18) displayed 92.9% and 94.4% seizure control with treatment, respectively. Isoflurane was used in the majority of cases. Hypotension was the only complication described. Conclusions: Oxford level 4, Grading of Recommendation Assessment Development and Education D evidence exists to support the use of isoflurane in refractory status epilepticus to obtain burst suppression. Insufficient data exist to comment on the efficacy of desflurane and xenon at this time.


Keywords: Inhalational anesthetics, volatile anesthetics, status epilepticus
doi:10.1017/cjn.2014.121

Refractory status epilepticus (RSE) poses significant challenges for both medical and surgical management.1-3 The standard frontline medications used for control of shorter duration seizures, and those patients in status epilepticus, are commonly ineffective in the setting of RSE.3 Changes in gamma aminobutyric acid-A (GABA<sub>A</sub>) receptors leads to unresponsiveness to GABA-mediated medications.4-6 Upregulation of p-glycoprotein leads to rapid export of phenytoin and phenobarbital molecules, impairing the action of these antiepileptic drugs (AEDs).7,8 In addition, significant upregulation of N-methyl D-aspartate receptors with prolonged seizures leads to glutamate mediated excitotoxicity, further potentiating epileptic activity. All of these described mechanisms are thought to be time-dependent.9 Thus, the rapid control of seizure activity in RSE is paramount. Numerous emerging therapies for those patients with RSE include but are not limited to therapeutic hypothermia, electroconvulsive therapy, and ketamine.

A potential last resort in RSE has been the use of volatile inhalational anesthetic agents to provide general anesthesia and suppress cortical activity. Few studies exist in the literature focusing on the use of modern inhalational anesthetics for control of refractory seizures.10-28 The goal of our study was to perform a systematic review of the literature on the effectiveness of modern inhalational anesthetic agents in controlling refractory seizures.

From the Section of Neurosurgery, Department of Surgery (FAZ, MW), University of Manitoba, Winnipeg, Canada; Section of Neurocritical Care (FAZ, KJZ, JT), Montreal Neurological Institute, McGill, Montreal, Canada; Section of Neurology (JT), Montreal Neurological Institute, McGill, Montreal, Canada; Section of Critical Care Medicine, Department of Medicine (LMG), University of Manitoba, Winnipeg, Canada; Section of General Surgery, Department of Surgery (LMG), University of Manitoba, Winnipeg, Canada. RECEIVED MAY 9, 2014. FINAL REVISIONS SUBMITTED NOVEMBER 21, 2014. Correspondence to: Frederick A. Zeiler, GB-1 820 Sherbrook Street, Health Sciences Center, Winnipeg, Manitoba, Canada R3A1R9. Email: umzeiler@cc.umanitoba.ca
METHODS

A systematic review using the methodology outlined in the Cochrane Handbook for Systematic Reviewers was conducted. The data were reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses. The review questions and search strategy were decided upon by the primary author and supervisor.

Search Question, Population, and Inclusion and Exclusion Criteria

The question posed for systematic review was: What is the effectiveness of modern inhaled anesthetic gas on control of RSE in humans? All studies, prospective and retrospective of any size based on human subjects, were included. The reason for an all-inclusive search was based on the small number of studies of any type identified by the primary author during a preliminary search of MEDLINE.

The primary outcome measure was electrographic seizure control, defined as: excellent (100% of patient response), moderate (greater than 50% of patient response), mild (less than 50% of patient response), and failure (0% response). This qualitative seizure response grading was used given the heterogeneous treatment response data on electrographic seizure control reported within the studies found. Secondary outcome measures were patient outcome (if reported), and adverse effects of the inhalational anesthetics.

Inclusion criteria were: All studies including human subjects whether prospective or retrospective, all study sizes, any age category, and the use of modern inhalational anesthetic gases (sevoflurane, isoflurane, desflurane, xenon) for seizure control in RSE. Exclusion criteria were: animal and non-English studies and treatment with the inhalational gases other than those mentioned in the inclusion criteria.

Search Strategy

MEDLINE, BIOSIS, EMBASE, Global Health, HealthStar, SCOPUS, and Cochrane Library from inception to March 2014 were searched using individualized search strategies for each database. The search strategy for MEDLINE can be seen in Appendix A of the supplementary material, with a similar search strategy used for the other databases. In addition, the World Health Organization’s International Clinical Trials Registry Platform was searched looking for studies planned or under way.

As well, meeting proceedings for the past ten years looking for ongoing and unpublished work based on inhalational anesthetics for seizures were examined. The meeting proceedings of the following professional societies were searched: Canadian Neurological Sciences Federation, American Association of Neurological Surgeons, Congress of Neurological Surgeons, European Neurosurgical Society, World Federation of Neurological Surgeons, American Neurology Association, American Academy of Neurology, European Federation of Neurological Science, World Congress of Neurology, Society of Critical Care Medicine, Neurocritical Care Society, World Federation of Societies of Intensive and Critical Care Medicine, American Epilepsy Society, the International League Against Epilepsy, American Society for Anesthesiologists, World Federation of Societies of Anesthesiologist, Australian Society of Anesthesiologists, International Anesthesia Research Society, Society of Neurosurgical Anesthesiology and Critical Care, Society for Neuroscience in Anesthesiology and Critical Care, and the Japanese Society of Neuroanaesthesia and Critical Care.

Finally, reference lists of any review articles or systematic reviews on seizure management were hand-searched for relevant studies on inhalational anesthetic usage for seizure control.

Study Selection

Using two reviewers (FZ and MW), a two-step review of all articles returned by our search strategies was performed. First, the reviewers independently screened all titles and abstracts of the returned articles to decide if they met the inclusion criteria. Second, the full text of the chosen articles was then assessed to confirm if they met the inclusion criteria and that the primary outcome of seizure control was reported in the study. Any discrepancies between the two reviewers were resolved by a third party (JT or LG).

Data Collection

Data were extracted from the selected articles and stored in an electronic database. Data fields included: patient demographics, type of study (prospective or retrospective), number of patients, type of anesthetic gas used, dose of anesthetic gas used, timing to administration of drug, duration of drug administration, time to effect of drug, how many other AEDs were used before implementation of inhalational anesthetic gas, degree of seizure control (as described previously), adverse effects, and patient outcome.

Quality of Evidence Assessment

Assessment of the level of evidence for each included study was conducted by an interdisciplinary panel of three independent reviewers using the Oxford criteria and the Grading of Recommendation Assessment Development and Education (GRADE) criteria for level of evidence. We elected to use two different systems to grade level of evidence given that these two systems are among the most commonly used. We believe this would allow a larger audience to follow our systematic approach in the setting of unfamiliarity with a particular grading system.

The Oxford criteria consist of a five-level grading system for literature. Level 1 is split into subcategories 1a, 1b, and 1c, which represent a systematic review of randomized control trials (RCTs) with homogeneity, individual RCTs with narrow confidence interval, and all or none studies, respectively. Oxford level 2 is split into 2a, 2b, and 2c, representing systematic review of cohort studies with homogeneity of data, individual cohort study or low-quality RCTs, and outcomes research, respectively. Oxford level 3 is split into 3a and 3b, representing systematic review of case-control studies with homogeneity of data and individual case-control study, respectively. Oxford level 4 represents case series and poor cohort studies. Finally, Oxford level 5 represents expert opinion.

The GRADE level of evidence is split into four levels: A, B, C, and D. GRADE level A represents high evidence with multiple high-quality studies having consistent results. GRADE level B represents moderate evidence with one high-quality study or multiple low-quality studies. GRADE level C evidence represents low evidence with one or more studies with severe limitations.
Finally, GRADE level D represents very low evidence based on either expert opinion or few studies with severe limitations. Any discrepancies between the grading of the three reviewers were resolved by a fourth reviewer.

**Statistical Analysis**

A meta-analysis was not performed in this study because of the heterogeneity of data within the articles and the presence of a small number of low-quality retrospective studies.

**RESULTS**

The results of the search strategy across all databases and other sources are summarized in Figure 1. Overall, 3633 articles were identified, with 3630 from the database search and 3 from the search of published meeting proceedings. After removing duplicate references, there were 2563 articles. By applying the inclusion/exclusion criteria to the title and abstract of the articles, we identified 70 articles that fit these criteria. Of the 70 identified, 67 were from the database search and 3 were from published meeting proceedings. Applying the inclusion/exclusion criteria to the full text documents, only 19 articles were eligible for inclusion in the systematic review, with 16 from database and 3 from meeting proceeding sources. The 51 articles that were excluded were done so because they either did not report details around the administration of inhaled anesthetic agents for seizure control, or because they were review articles. Reference sections from these review articles were searched by hand for any other articles missed in the database search, with none being identified.

Of the 19 articles included in the review, all were original studies. Kofke et al included patient data from 2 of the other 19 articles. Similarly, Kofke et al contained data from 1 of the 19 articles. The patient data repeated in these two studies were not included in the tabulation of data for this review in order to avoid including the same individual patient data multiple times. Three articles were published meeting abstracts.

There were 18 retrospective studies, all original studies, and 1 prospective study. Thus the potential for significant publication bias is present. Within the retrospective studies, eight were retrospective case series, and the remaining ten were retrospective case reports. The retrospective case series were composed of six single-center reviews and two multicenter reviews. The one prospective study included in the systematic review was a prospective cohort study with no control group. Fourteen articles described the use of inhaled anesthetic in adults, with Ropper et al containing duplicate patient data. Nine studies described pediatric patients, with one containing duplicated data. Four of the 19 studies have combined adult and pediatric patient populations with Kofke et al not...
separating adult from pediatric data and thus being included in the adult summary.

Four different inhalational anesthetic agents were reported. Isoflurane was used in 18 studies,10–12,18–28 desflurane in 2,23,28 and xenon in 1.11 Halothane was used in two studies,12,23 but its effect was not analyzed given its current lack of use as a modern anesthetic gas.

Between all studies, 46 patients were studied using modern inhalational anesthetic gas for control of their seizures (mean 2.4 patients/study; range: 1–9 patients/study). Eighteen patients were pediatric (age range: 8 months to 17 years), with the exclusion of data from Kofke et al18 because adult and pediatric data were not separated within the abstract. Twenty-eight patients were adult (age range: 18–71 years). A variety of underlying etiologies for RSE existed in both the adult and pediatric populations.

Study demographics and patient characteristics for all studies can be seen in Table 1, whereas treatment characteristics and seizure outcome are reported in Table 2.

Inhalational Anesthetic Treatment Characteristics

Adults

The literature on inhalated anesthetics for seizure control in the adult population yielded 13 studies with original patient data. Kopper et al23 was not included in the adult summary because of data duplication. Within these 13 studies,13–16,18–20,22,24–26,28 11 used isoflurane only.13–16,18–20,22,24–26,28 with a minimum alveolar concentration (MAC) ranging from 0.5 to 5.0% (commonly used dose across all studies was 0.5–2.0%). One study25 used isoflurane in isolation at a MAC ranging from 0.5 to 5.0% in five patients, and a combination of desflurane/isoflurane with a MAC of 1.0–4.0%/0.1–0.66% for one patient. The final study for adults used desflurane for 13 days, followed by isoflurane for 13 days at a MAC of 1.0–4.0% and 0.1 and 0.66%, respectively.28

Duration of treatment before inhalational anesthetic administration was documented in nine adult studies, ranging from 8 hours to 60 days (median = 45 hours), with patients on various numbers of AEDs before anesthetic gas, ranging from 1 to 15 (mean = 6.8, median = 7). Similarly, the duration of inhalated anesthetic treatment was described in 10 of the 13 adult studies, with treatment duration ranging from 5 hours to 32 days (median = 30.3 hours, mean = 112.0 hours). Treatment characteristics for the adult studies can be seen in Table 2.

Pediatrics

Within those nine studies describing inhalated anesthetic use in the pediatric population,10–13,17,19,21,23 one study was not included because of duplication of patient data,17 whereas a second study,18 failed to separate pediatric from adult data and thus had its data included in the adult section of the review. Among the seven remaining studies, isoflurane was used in isolation in five articles10,13,19,21,23 with a MAC of 0.5–5.0% (usual range = 0.5–2.5%). One study used halothane and isoflurane at unknown concentrations.19 Finally, one study focused on xenon anesthetic in asphyxial neonates at a concentration of 30%.11

Duration of treatment before inhalational anesthetic administration was documented in five pediatric studies, ranging from 12 hours to 103 days (median = 312 hours), with patients on various numbers of AEDs before ketamine, ranging from 0 to 10 (median = 4, mean = 5). Similarly, the duration of inhalated anesthetic treatment was described in four studies, ranging from 1 hour to 85 days (median = 29 hours). Treatment characteristics for the pediatric studies can be seen in Table 2.

Seizure Response

Adults

Seizure control upon inhalated anesthetic administration in the adult population was documented as excellent (complete response in all patients) in 12 of 14 studies, taking into account duplicate patient data. Failure of treatment response in all patients occurred in two studies with a total of two patients within these studies.24,27

Across all 13 adult studies, with nonduplicate patient data, a total of 26 of 28 adult patients (92.9%) were described as having complete electrographic seizure responsiveness to inhalational anesthetics, namely isoflurane. Isoflurane was effective in all but two patients (7.7%) when used as the only inhalated anesthetic.24,27

The timing of electrographic response to isoflurane anesthesia was described as “immediate” in all 26 adults patients that demonstrated a response, typically within minutes when documented. An unspecified majority of patients required titration of the isoflurane MAC to achieve burst suppression.

Desflurane was inferior to isoflurane in controlling seizure activity and achieving burst suppression in the two adult patients within which it was used.25,28 Desflurane achieved seizure reduction in the two adult studies, but burst suppression was not achieved, even with MAC reaching 4.0%. Isoflurane was used as a salvage agent to achieve seizure control in these two studies.

Regardless of the inhalated anesthetic used, seizure activity tended to return upon cessation of the volatile gas treatment.

Pediatrics

Seizure control in the pediatric studies, with nonduplicate patient data, was documented as excellent in six of the seven studies,11–13,17,19,21,23 A total of 17 of 18 pediatric patients (94.4%) had seizure control with inhalational treatment. Failure of treatment response was described in one pediatric patient (5.6%).10

Isoflurane failed to control the refractory seizures in 1 of 13 patients (7.7%) in which it was used. This patient had suspected Rasmussen’s encephalitis,10 requiring surgical intervention to halt seizure activity. The timing to response of seizures to isoflurane in children was typically immediate, but required titration to achieve burst suppression. As in the adult population, cessation of isoflurane seemed to precipitate seizures in most patients.

Xenon was used in asphyxial neonates and displayed excellent results in the five children with seizures.11 Seizures seemed to return with cessation of xenon.

Adverse Effects of Inhalational Anesthetics

Adverse effects were seldom described within the 19 articles reviewed. Four studies described hypotension temporally associated to isoflurane treatment and required vasopressors.19,21,26,28 Finally, one study13 described nonspecific MRI changes in the cerebellum and thalamus potentially attributable to long-term isoflurane administration of more than 30 days. However, these changes occurred in the setting of severe RSE and may not reflect anesthetic gas treatment.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of patients treated with anesthetic gas</th>
<th>Study type</th>
<th>Setting</th>
<th>Article location</th>
<th>Mean age (y)</th>
<th>Etiology of seizures</th>
<th>Mean no. of medications before anesthetic gas</th>
<th>Mean time until anesthetic gas administration (d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexopoulos et al^{10}</td>
<td>10 (only 1 had inhalational treatment)</td>
<td>Retrospective case series</td>
<td>Single center</td>
<td>Manuscript</td>
<td>22 months</td>
<td>Possible Rasmussen’s encephalitis</td>
<td>4</td>
<td>Unknown</td>
</tr>
<tr>
<td>Azzopardi et al^{11}</td>
<td>14 (only 5 had seizures)</td>
<td>Prospective cohort</td>
<td>Multicenter</td>
<td>Manuscript</td>
<td>Neonates: 36-43 wk GA</td>
<td>Asphyxial encephalopathy</td>
<td>0</td>
<td>72 h of hypothermia concurrently</td>
</tr>
<tr>
<td>Demulder et al^{12}</td>
<td>3</td>
<td>Retrospective case series</td>
<td>Single center</td>
<td>Meeting abstract</td>
<td>5-9</td>
<td>Pearson syndrome</td>
<td>8</td>
<td>Unknown</td>
</tr>
<tr>
<td>Fugate et al^{13}</td>
<td>2</td>
<td>Retrospective case series</td>
<td>Single center</td>
<td>Manuscript</td>
<td>25 and 4</td>
<td>Idiopathic in both</td>
<td>5 and 7 (plus ketogenic diet)</td>
<td>5 and 13</td>
</tr>
<tr>
<td>Hilz et al^{14}</td>
<td>1</td>
<td>Retrospective case Report</td>
<td>Single Center</td>
<td>Manuscript</td>
<td>35</td>
<td>Epilepsy since birth, noncompliant with medications</td>
<td>5</td>
<td>Unknown</td>
</tr>
<tr>
<td>Hughes et al^{16}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>28</td>
<td>Thallium poisoning</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Kofke et al^{17}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>30</td>
<td>Chronic encephalitis</td>
<td>7</td>
<td>2 mo</td>
</tr>
<tr>
<td>Kofke et al^{18*}</td>
<td>6</td>
<td>Retrospective case series</td>
<td>Multicenter</td>
<td>Meeting abstract</td>
<td>Range: 2-30</td>
<td>Idiopathic (2); viral encephalitis (2); AVM (1); organophosphates (1)</td>
<td>3</td>
<td>Unknown</td>
</tr>
<tr>
<td>Kofke et al^{19,1}</td>
<td>9 (11 occasion of RSE)</td>
<td>Retrospective Case series</td>
<td>Multicenter</td>
<td>Manuscript</td>
<td>28.5 (range: 2-64)</td>
<td>Idiopathic (5); AVM (2); Aneurysm clipping (1); organophosphates (1); post liver transplant (1); bacterial meningitis (1)</td>
<td>2 (range: 1-11)</td>
<td>17.5 (range: 8-40 d)</td>
</tr>
<tr>
<td>Kofke et al^{20}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>21</td>
<td>Idiopathic</td>
<td>9</td>
<td>44 h</td>
</tr>
<tr>
<td>Lippert et al^{21}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>8 mo</td>
<td>Known epilepsy, noncompliant with medications given gastroenteritis</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>Meeke et al^{22}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>32</td>
<td>Known epilepsy, CP</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Mirsattari et al^{23}</td>
<td>7</td>
<td>Retrospective case series</td>
<td>Single center</td>
<td>Manuscript</td>
<td>42.4 (range: 17-71)</td>
<td>Cryptogenic (2); silver toxicity (1); noncompliance (1); encephalitis (1); hemorrhage leukoencephalitis (1); ODG (1)</td>
<td>10 (range: 7-15)</td>
<td>19 (range: 1-103)</td>
</tr>
<tr>
<td>Robakis et al^{24}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>30</td>
<td>Idiopathic</td>
<td>13</td>
<td>Unknown</td>
</tr>
<tr>
<td>Ropper et al^{25*}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>29</td>
<td>Encephalitis</td>
<td>8</td>
<td>32</td>
</tr>
<tr>
<td>Sakaki et al^{26}</td>
<td>4</td>
<td>Retrospective case series</td>
<td>Single center</td>
<td>Manuscript</td>
<td>35.3 (range: 24-44)</td>
<td>Post-resection: tumor (2); AVM (2)</td>
<td>3 (range: 3-5)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Savard et al^{27}</td>
<td>1</td>
<td>Retrospective case series</td>
<td>Single center</td>
<td>Meeting abstract</td>
<td>27</td>
<td>POLG mitochondrial disorder</td>
<td>13 (plus ECT)</td>
<td>Unknown</td>
</tr>
<tr>
<td>Sharp et al^{28}</td>
<td>1</td>
<td>Retrospective case report</td>
<td>Single center</td>
<td>Manuscript</td>
<td>71</td>
<td>Idiopathic</td>
<td>7</td>
<td>24 h</td>
</tr>
</tbody>
</table>

*Kofke et al^{18} is a meeting abstract that reports the case from Kofke et al^{17} and Ropper et al^{25}; patient data from Kofke et al and Ropper et al^{25} were not included in the tabulation of results in order to avoid duplication of patient data.

*Kofke et al^{19} contains the patient data from Kofke et al^{17} as well.

AVM = arteriovenous malformation; CP = cerebral palsy; ECT = electroconvulsive therapy; ODG = oligodendroglioma.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Anesthetic gas used</th>
<th>Anesthetic gas dose</th>
<th>MAC (h)</th>
<th>Mean duration of anesthetic gas (d)</th>
<th>Electrographic seizure response</th>
<th>Rating of seizure response</th>
<th>Adverse effects to ketamine</th>
<th>Patient outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexopoulos et al</td>
<td>Isoflurane</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>No Response</td>
<td>Failed</td>
<td>Not described</td>
<td>Required surgery for seizure reduction</td>
</tr>
<tr>
<td>Azzopardi et al</td>
<td>Xenon</td>
<td>30%</td>
<td>Unknown</td>
<td>1</td>
<td>All stopped with xenon, recurrence with cessation of therapy</td>
<td>Excellent</td>
<td>Not described</td>
<td>Unknown</td>
</tr>
<tr>
<td>Demulder et al</td>
<td>Halothane and isoflurane</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Immediate cessation of seizures (returned after stopping gas)</td>
<td>Excellent</td>
<td>Not described</td>
<td>Unknown</td>
<td></td>
</tr>
<tr>
<td>Fugate et al</td>
<td>Isoflurane</td>
<td>MAC = 1% tiritated to burst supression (range: 0.5-2.5%)</td>
<td>1382.4 and 1975.2</td>
<td>34 and 85</td>
<td>Burst suppression achieved</td>
<td>Excellent</td>
<td>Potential FLAIR hyperintensity in cerebellum and thalamus related to treatment duration</td>
<td>Vegetative state and minimally conscious</td>
</tr>
<tr>
<td>Hilz et al</td>
<td>Isoflurane</td>
<td>MAC = 0.5% initially, titrated to 1.5% to achieve slowing</td>
<td>8.75 (over two occasions)</td>
<td>6 h, 45 min</td>
<td>Immediate reduction in seizure activity</td>
<td>Excellent</td>
<td>None</td>
<td>Worse cognitive impairment</td>
</tr>
<tr>
<td>Hilz et al</td>
<td>Isoflurane</td>
<td>MAC = 1.5% initially for control, then titrated to seizures on EEG Range (0.8-1.2%)</td>
<td>168.0</td>
<td>7</td>
<td>Cessation of seizure within 4 min of therapy (returned with MAC &lt;0.8%)</td>
<td>Excellent</td>
<td>None</td>
<td>Vegetative state</td>
</tr>
<tr>
<td>Hughes et al</td>
<td>Isoflurane</td>
<td>MAC = 0.5% (maximum 0.7%)</td>
<td>24.0</td>
<td>2</td>
<td>Immediate control of seizures</td>
<td>Excellent</td>
<td>None</td>
<td>Discharged home</td>
</tr>
<tr>
<td>Kotke et al</td>
<td>Isoflurane</td>
<td>MAC = 0.5% initially, titrated to EEG response (range: 0.3-1.2%)</td>
<td>24.0</td>
<td>2</td>
<td>Immediate control of seizures</td>
<td>Excellent</td>
<td>None</td>
<td>Discharged home</td>
</tr>
<tr>
<td>Kotke et al</td>
<td>Isoflurane</td>
<td>Range: 0.5-3.0% MAC, titrated to EEG burst suppression</td>
<td>Unknown</td>
<td>31.5 h (range: .54 h)</td>
<td>Immediate response</td>
<td>Excellent</td>
<td>None</td>
<td>Uncontrolled seizures off of isoflurane in 3 (2 died)</td>
</tr>
<tr>
<td>Kotke et al</td>
<td>Isoflurane</td>
<td>Range: 0.5-5% MAC, titrated to burst supression</td>
<td>Unknown</td>
<td>29 h (range: 1-55 h)</td>
<td>Immediate response (seizure reduction then burst supression) SE resumed in 8/11 episodes of RSE after cessation of isoflurane</td>
<td>Excellent</td>
<td>Hypotension in all requiring vasopressors</td>
<td>6 of 9 patients died, 3 severe cognitive deficits</td>
</tr>
<tr>
<td>Kotke et al</td>
<td>Isoflurane</td>
<td>MAC = 0.5% initially, titrated to EEG</td>
<td>Unknown</td>
<td>7.5 h</td>
<td>Immediate response</td>
<td>Excellent</td>
<td>None</td>
<td>Discharged Home, under care of parents</td>
</tr>
<tr>
<td>Lippert et al</td>
<td>Isoflurane</td>
<td>MAC = 1% initially, titrated to EEG (max 2.0%)</td>
<td>1.0</td>
<td>1</td>
<td>Immediate response (burst supression, then silent EEG)</td>
<td>Excellent</td>
<td>None</td>
<td>Discharged home</td>
</tr>
<tr>
<td>Meeke et al</td>
<td>Isoflurane</td>
<td>MAC = 0.5-1.0%</td>
<td>45.0</td>
<td>45</td>
<td>Immediate response (10 min)</td>
<td>Excellent</td>
<td>None</td>
<td>Died of sepsis day 53 into ICU stay</td>
</tr>
<tr>
<td>Mirsattari et al</td>
<td>Isoflurane (7)/ desflurane (1)</td>
<td>Isoflurane: Mean maximum MAC = 1.2-5.0% Desflurane: MAC = 1-4%</td>
<td>173 ± 159 (range: 12-277)</td>
<td>11 ± 9 (range: 2-26)</td>
<td>Immediate response (burst Suppression within minutes)</td>
<td>Excellent</td>
<td>Hypotension requiring increase in vasopressors</td>
<td>GOS of 5 in 2 patient; GOS of 4 in 2 patients; GOS of 1 (died) in 3 patients.</td>
</tr>
<tr>
<td>Robakis et al</td>
<td>Isoflurane</td>
<td>Unknown</td>
<td>Unknown</td>
<td>Unknown</td>
<td>No response</td>
<td>Failed</td>
<td>Unknown</td>
<td>Persistent vegetative state</td>
</tr>
<tr>
<td>Kopper et al</td>
<td>Nitrous oxide/ halothane trial x 1</td>
<td>Nitrous oxide/halothane: (60% 1.25%) Isoflurane: Range: 0.25-2.0% MAC</td>
<td>Unknown</td>
<td>5</td>
<td>Immediate response with isoflurane Mild suppression of seizures with nitrous/halothane</td>
<td>Excellent with isoflurane</td>
<td>Unknown</td>
<td>Died</td>
</tr>
</tbody>
</table>
Outcome

Patient outcome was reported sparingly in most studies, with some documentation in 17 of the 19 articles. Two manuscripts failed to document outcome.11,12 The overall outcome of the patients was variable, with only four studies indicating patients (n = 4) returning home.16,17,20,21 The majority of patients suffered moderate to severe disability or died as a result of complications or uncontrollable seizures when taken off of inhalational anesthetics.

All studies describing treatment failure had poor outcomes. Within the three studies describing treatment failure,10,24,27 the final outcome was unknown in one patient,10 vegetative state in one,24 and dead in one patient.27

Level of Evidence for Inhalational Anesthetics

Based on three independent reviewers, there were 19 studies reviewed, with all representing Oxford level 4 evidence in support of administering modern inhalational anesthetics for refractory seizures. Similarly, within the adult and pediatric population, all studies met the criteria for GRADE D level of evidence in support of the use of modern inhaled anesthetics for RSE.

Overall, we can recommend Oxford level 4 and GRADE D evidence for the use of isoflurane to control RSE. Given the lack of sufficient data for other inhalational anesthetics in the setting of RSE, we cannot make any formal comments on their efficacy. Summary of the level of evidence can be seen in Table 3.

Discussion

The use of modern inhalational anesthetic agents to control seizures has recently emerged as a salvage therapy in refractory cases. The numerous properties of inhalational anesthetics provide them with a unique means of modulating cerebral epileptogenicity. First, anesthetic gas is easily transported into the lipophilic environment of the central nervous system. Second, inhalational anesthetics are easily titrated to electroencephalographic response.23 Finally, anesthetic gas provides cerebral protection via inhibition of glutamate-mediated N-methyl-D-aspartate receptor excitotoxicity, while also activating GABAA receptors.38

Not all modern inhalational gases are equivalent, however. Sevoflurane has demonstrated in both animal and human studies to be pro-epileptogenic and therefore has not emerged as a potential therapy for RSE. Thus the antiepileptic properties of isoflurane and desflurane seem to be superior, potentially via more potent N-methyl-D-aspartate inhibition.42 Similarly, the safety of prolonged administration provides both isoflurane and desflurane a potential advantage over sevoflurane and its predecessors halothane and enflurane. Xenon inhalational anesthetic gas has been sparingly reported in the literature and thus conclusive comments on its efficacy in RSE are limited.

The limitations of inhalational anesthetic treatments for RSE are few, but important. First, prolonged administration of fluorinated anesthetic gas has been demonstrated to lead to a rise in inorganic serum fluoride levels, of which the effects are undetermined. Recent animal literature indicates a dose-dependent increase in hepatic, renal, and pulmonary injury secondary to these fluorinated byproducts with isoflurane administration. Second, with sevoflurane administration, fluorinated byproducts have the potential to bind with carbon dioxide molecules, leading to toxic compounds that
impair renal function. Similar renal dysfunction has been reported with isoflurane administration. Third, the systemic cardiovascular effects of inhalation anesthetics need to be considered. Hypotension is a common side effect, typically requiring vasopressor to augment mean arterial pressures to within an acceptable range. Despite the cardiovascular depressant effect of inhalational gases, the effect seems to be less than compared with other standard intravenous anesthetic agents used in RSE. Isoflurane is not immune to this effect, with recent animal literature implicating a calcium mediated myocardial depression in high doses. Finally, isoflurane has recently been implicated in neurotoxicity and apoptotic-induced neuronal death in elevated concentrations. This is of concern, given the goal of its use in RSE is in prevention of neurological morbidity with prolonged/uncontrolled seizures. Thus, one will have to weigh the risks and benefits of its use in RSE before implementation.

Given the paucity of literature to date using inhaled anesthetic gases in the setting of RSE, we decided to perform this systematic review to provide a summary of the effect of modern inhalational gases (sevoflurane, isoflurane, desflurane, and xenon) on control of refractory seizures. Through our review, we identified 19 articles—16 manuscripts and 3 meeting proceedings—using modern inhalational anesthetics to control refractory seizures. A total of 46 patients were described in these articles, with 28 being adult and 18 pediatric. The majority of the studies was retrospective case reports/series, with only 1 being prospective cohort study. Isoflurane was used in all but one study, where xenon was used. Desflurane was used with isoflurane in two studies. Seizure control with inhalation gas occurred in 92.9% and 94.4% of adult and pediatric patients, respectively, with the majority responding almost immediately upon gas administration. Burst suppression was achievable with titration. Desflurane was ineffective at achieving burst suppression, even at high MAC. Isoflurane was used as a salvage treatment in these cases. Xenon controlled seizures in all neonates with asphyxia seizures. Epileptic activity returned in most patients after cessation of inhalational anesthetics. In the secondary outcomes, only minimal adverse events were associated with inhalational anesthetic gas administration, with hypotension commonly described. Unfortunately, patient outcome data were too sparingly documented for any strong conclusion, though there was a trend to worse outcome in those whom failed therapy. All studies were an Oxford level 4 for quality, with all of adult and pediatric studies being a GRADE D level of evidence. A meta-analysis was not possible given the heterogeneous, retrospective nature of the majority of studies available. Thus, based on this review, we can currently provide Oxford level 4 for quality, with all of adult and pediatric studies being a GRADE D level of evidence. A meta-analysis was not possible given the heterogeneous, retrospective nature of the majority of studies available. Thus, based on this review, we can currently provide Oxford level 4, GRADE D recommendations for the use of isoflurane for RSE. Given the paucity of data, similar conclusions for desflurane and xenon cannot be made at this time.

Important trends can be seen within our review. First, isoflurane appears effective (>90% responsiveness) in controlling RSE in a variety of underlying neuropathology; however, similar comments on desflurane and xenon cannot be made.
Desflurane does appear less effective, however, requiring isoflurane salvage in the studies identified. Second, the antiepileptic effects of isoflurane are present even in those cases with RSE of up to and exceeding 2 months’ duration. Third, prolonged administration of isoflurane, up to 85 days, does not seem to have any significant side effects. Hypotension was commonly described as the side effect in the studies identified, although this is also a common effect of intravenous anesthetics used in RSE. One study identified nonspecific MRI changes in the thalamus and cerebellum that potentially could be attributable to inhalational therapy.13 No reports of renal dysfunction were described. Caution must be taken, however, because the lack of adverse events with isoflurane administration is likely related to significant publication bias, reporting only those cases with positive outcomes on seizure control in RSE. Finally, both early (within 1 hour) and late implementation (at 85 days) of isoflurane seem effective in achieving burst suppression, thus supporting its potential efficacy at any point during the management of RSE.

Our review has significant limitations. First, the small number of studies identified, all with small patient populations, makes it difficult to generalize to all RSE patients. Second, the retrospective heterogeneous nature of the data makes it difficult to perform a meaningful meta-analysis, resulting in a strictly descriptive analysis. Third, the heterogeneity of prior treatments, time to inhalational anesthetic administration, and variable MAC and duration of therapy leave the data on seizure responsiveness difficult to interpret. It is even more difficult, on the basis of this and duration of therapy leave the data on seizure responsiveness difficult to interpret. It is even more difficult, on the basis of this review. Consideration should be made for a future prospective study of inhalational anesthetics in RSE, given the heterogeneous data and significant publication bias identified within this review. The small number of cases identified in this review highlights the need for multicenter databases for RSE to better outline the role of nonconventional therapies.

CONCLUSIONS

There currently is Oxford level 4, GRADE D evidence to potentially support the use of isoflurane to achieve burst suppression for RSE in the adult and pediatric populations. Further prospective study of inhalational anesthetics in RSE is warranted.

DISCLOSURES

FZ is a Health Sciences Center Foundation research recipient and received a research grant for the project on optic nerve sheath diameter.

REFERENCES


